🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In #JACCHF Andreas Gevaert reports exercise training does not induce significant changes in vascular function at 3 or 12 months in patients with HFpEF jacc.org/doi/10.1016/j.…

Importance of dynamic invasive hemodynamic assessment for PH to evaluate for occult HFpEF, especially if high pre-test probability #ISHLT2023 #PHAcademy The ISHLT

In print today! Our JACC Journals Scientific Statement on #HFpEF: diagnosis, mechanisms and treatment! Kudos to this amazing team: Barry Borlaug Jennifer Ho Sanjiv Shah Sanjiv J. Shah, MD! jacc.org/doi/abs/10.101… Johns Hopkins Medicine Johns Hopkins Cardiology American College of Cardiology Maryland Chapter, American College of Cardiology

“Exercise is medicine” is a global health initiative. The result of rehabilitation therapy in older acute #heartfailure patients (REHAB-HF) study shows that older acute HF patients can improve cardiovascular fitness by setting the correct exercise dose. doi.org/10.20517/jca.2…

Grateful to share results of PARAGLIDE-HF on behalf of tremendous team effort. Sac/Val vs Val in 466 pts w HF and EF>40% with recent WHF. Positive trial for NTproBNP reduction; CV & renal endpts favored esp in EF<|=60% jacc.org/doi/10.1016/j.…

Really enjoyed working on this project with mentor Adam DeVore, MD, MHS and the team. Compelling data on the potential superiority of LV GLS for risk stratification in HFmrEF/HFpEF; more work needed on role in treatment heterogeneity and response. Robert Mentz, MD Michael Felker Anita Kelsey, MD, MBA

#EchoFirst Features Beyond Ejection Fraction and Associated Outcomes in Patients With #HFmrEF or #HFpEF In this large, real-world HF with mildly reduced or preserved #LVEF population, echo features, led by LV #GLS, were associated with adverse outcomes irrespective of LVEF

Contractile function, not EF? Anyone? Published today Circ: Heart Failure Great work by Anthony Peters, Adam DeVore, MD, MHS and colleagues Duke Cardiology with important lessons for all of us managing patients with HF and "good" EF! EF might be normal, but is contractility? ahajournals.org/doi/full/10.11…

"Transplantation Outcomes with Donor Hearts after Circulatory Death" 🚨Incredibly impactful data on DCD outcomes🚨 Congrats Jacob Niall Schroder Adam DeVore, MD, MHS Sarah Casalinova ben bryner Maryjane Farr MD MSc, FACC FAST FHFSA FAHA @MRMehraMD et al Duke Heart Duke Surgery Duke Health NEJM nejm.org/doi/full/10.10…

Simpub late breaker #HFA2024 & JAMA V142I TTR CV burden HFH risk @ 63 (mostly HFrEF) and dth @ 72 Women/men similar Carriers live 2-2.5 years less ➡️loss of ~1million years of life in US 🙏 scottdavidsolomon Svati Shah Robert Mentz, MD Sadiya Khan Parag Goyal MD MSc marianna fontana

#ACCQuality24 Chair Olivia Gilbert shares her highlights from Day 1 in San Antonio including: ✅ Ami Bhatt, MD's talk on evolving technologies ✅ Discussion on best practices in mortality review ✅ Intriguing poster presentations Check out the Day 2 schedule here 👉

HuMAIN Phase II study of HU6 in obesity HFpEF More visceral fat loss vs lean mass loss. Overall appears safe. Pivotal Phase III studies needed to understand impact on clinical endpoints. Proud to see our work presented HFSA today. Mikhail Kosiborod Saint Luke's Mid America Heart Institute

This week's #Cardiology Regional Grand Round will focus on #obesity and #heartfailure. Join us for a presentation by Dr. Josephine Harrington (@jlharrington_md) from CPC Clinical Research and CU School of Medicine. McMaster Health Sciences McMaster University Department of Medicine McMaster Heart Function Education Harriette Van Spall, MD MPH 🇨🇦 #cardiotwitter

In KETO-HFpEF, we integrated CPET, echo, lung US, tonometry, metabolites, isotope tracer, & leg MRI. Ketone ester didn't ⬆️ exercise, despite ⬇️filling pressure & glucose use at rest/exercise Simpub #ACC25 #JACCHF 🙏 #PZamani Margulies Lab &team Penn Cardiology Duke Heart

Wow! 😳 P3 #ZENITH RCT stopped early for overwhelming efficacy Sotatercept, an activin signaling inhibitor already proven to slow progression in lower risk PAH, now shown to dramatically ⬇️ death or worsening in advanced PAH HR 0.24 (0.13-0.43) P<0.001 nejm.org/doi/full/10.10…

New in JACC HF: Would you discontinue GDMT in patients with #HFimpEF? If so, how would you select the ones with lowest risk of deterioration? shorturl.at/rGHe7